Note: Ingredients listed on restricted chemical lists
EC/CAS
5989-27-5
Name of the chemical
(R)-p-mentha-1,8-diene
Concentration
N/A
EC/CAS
872-50-4
Name of the chemical
N-Methyl-2-Pyrrolidone; 1-methyl-2-pyrrolidone (NMP)
Concentration
N/A
General Information
Revision date
2006-09-07
Product name
KWICK KLEAN
Product Synonyms
S HEE
Manufacturer Name
SIERRA CORP
Emergency telephone
1-800-424-9300
Icons in SDS
Company Information
company name
SIERRA CORP
Section 2
Health hazards
IDENTIFICATION
Principle Routes of Exposure
Skin contact, eye contact, and inhalation. EFFECTS OF ACUTE EXPOSURE: EYES: Contact with eyes may cause irritation including burning, watering, and redness. SKIN: Contact may cause mild skin irritation including redness, burning, and drying and cracking of skin. Continued exp may develop into dermatitis. Solvents can penetrate the skin and cause systematic effects similar to those under inhalation symptoms. INHALATION: High vapor concentrations are irritating to the eyes and respiratory tract, may cause headaches, dizziness, anesthesia, asthma, drowsiness, unconsciousness, and other central nervous system effects, and possibly death. INGESTION: Can cause gastrointestinal irritation, nausea, vomitting and diarrhea. Small amounts aspirated into the respiratory system during ingestion or vomiting may cause mild to severe pulmonary injury.
Potential chronic health
Reports have associated repeated and prolonged occupational overexposure to solvents with permanent brain and nervous system damage (Sometimes referred to as Solvent or Painter's Syndrome). Intentional misuse by deliberately concentrating and inhaling this material may be harmful or fatal. Chronic exposure may also cause damage to the respiratory system, lungs, eyes, skin, gastrointestinal tract, liver, spleen and kidneys. Repeated skin contact may cause persistant irritation or dermatitis.
Medical Conditions Generally Aggravated by Exposure
Conditions aggrevated by exposure may include skin disorders, respiratory (asthma-like) disorders, and pre-existing liver or kidney conditions. SECTION